A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Seagen Inc.
Seagen Inc.
Travera Inc
National Institutes of Health Clinical Center (CC)
A2 Biotherapeutics Inc.
National Institutes of Health Clinical Center (CC)
Azienda Ospedaliero-Universitaria di Parma
A2 Biotherapeutics Inc.
St. Jude Children's Research Hospital
University of Nebraska
Takeda
VM Oncology, LLC
Bristol-Myers Squibb
Dana-Farber Cancer Institute
Actym Therapeutics, Inc.
TCR2 Therapeutics
Azienda Ospedaliera di Padova
A2 Biotherapeutics Inc.
University of Pittsburgh
Azienda USL Reggio Emilia - IRCCS
Cancer Research UK
Alliance for Clinical Trials in Oncology
BerGenBio ASA
Taproot Health
Sheffield Teaching Hospitals NHS Foundation Trust
Travera Inc
NGM Biopharmaceuticals, Inc
UTC Therapeutics Inc.
Pfizer
Second Affiliated Hospital of Guangzhou Medical University
NGM Biopharmaceuticals, Inc
Massachusetts General Hospital
Quadriga Biosciences, Inc.
MacroGenics
Abramson Cancer Center at Penn Medicine
Shenzhen BinDeBio Ltd.
National Institutes of Health Clinical Center (CC)
University of Magdeburg
National Institutes of Health Clinical Center (CC)
Swiss Cancer Institute
National Institutes of Health Clinical Center (CC)
NHS Greater Glasgow and Clyde
Masonic Cancer Center, University of Minnesota
Morphotek
Stanford University
Chinese PLA General Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Morphotek
INSYS Therapeutics Inc
University of Chicago